Galapagos
Galapagos NV (GLPG) is a biotechnology company focused on the discovery and development of innovative medicines for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on drug discovery and development in areas such as inflammation, fibrosis, and other diseases. Galapagos is known for its proprietary platform, which integrates genetics, biology, and drug discovery to develop novel therapies, including its lead product, filgotinib, which targets inflammatory diseases.